Search Results for: SPRINT

Clinical Trials: You Can’t Always Get What You Want

–Trial investigators have lost control of their trials’ messages. Editor’s Note: The following is a lightly edited version of a talk I presented (without slides!) at the CVCT workshop in Washington, DC earlier this week. The topic was the changing role of media in communicating the results of clinical trials. When it comes to the…

Click here to continue reading…

New Blood Pressure Guideline Sets Lower 130/80 Threshold

Expanded guideline means more than 100 million people have high blood pressure. The new US blood pressure guideline lowers the definition of high blood pressure to 130/80 mm Hg. This means that more than 100 million adults will now have high blood pressure, though many will be unaware of the diagnosis. The 192 page guideline…

Click here to continue reading…

Upcoming US Guideline Will Likely Set 130/80 As New Blood Pressure Target

–The highly anticipated AHA/ACC BP guideline will be published in November. The new magic number will be 130 over 80 mm Hg. That’s the new blood pressure goal that many hypertension experts say will be the centerpiece of the new US blood pressure guidelines. The new guideline will be introduced next month in Anaheim during the…

Click here to continue reading…

Aggressive BP Targets Will Hike Falling Risk in Older Patients

–Another paper raises new questions about applying SPRINT in the real world Applying the intense blood pressure goals used in SPRINT in a real world elderly population might lead to a dramatic increase in injurious falls, according to a new study from Ireland published in JAMA Internal Medicine. The Systolic Blood Pressure Intervention Trial (SPRINT)…

Click here to continue reading…

New Review Supports Aggressive BP Targets

–Meta-analysis supports a systolic blood pressure target of 120 mm Hg A new systematic review and network meta-analysis lends support to more aggressive blood pressure targets. In recent years US guidelines have recommended more relaxed systolic blood pressure targets, ranging from 140 mm Hg to 150 mm Hg, for people with hypertension. But the results…

Click here to continue reading…

2016: Great Year Or Greatest Year Ever?

Editor’s note: Once again Larry was too depressed to write the 2016 yearly review. (Actually, he’s hiding under his bed.) Veteran healthcare journalist and eternal optimist Candide Corn has again kindly agreed to take over the task this year. Candide’s motto is “all is for the best in the best of all possible worlds.” What a great year!…

Click here to continue reading…

Can 50 Million Blood Pressure Prescriptions Each Year Be Wrong?

–For decades physicians may have been prescribing the wrong diuretic. Now an innovative new trial will settle the question. A radically innovative large new VA trial will finally shed light on a decades-old unresolved question that could have important public health implications. According to guidelines thiazide diuretics are the first-line treatment for hypertension. Hydrochlorothiazide accounts…

Click here to continue reading…

How Does HOPE-3 Change Thinking About Primary Prevention?

–The study lends strong support for statins but delivers a mixed message for antihypertensives. The widely reported results of HOPE-3 may bolster the case for primary prevention with statins and blood pressure drugs. But the trial also makes clear that the benefits, though real, are also modest, and may not be evenly distributed between statins…

Click here to continue reading…

Study Shows Why Sham Controls Are Necessary For Device Trials

— If we can melt the ice-caps then surely we can understand our own fallibility, says one UK cardiologist. The strongest known force in the universe is the ability of the human mind to deceive itself. If we know something to be true then we find the evidence to prove it. There is no better…

Click here to continue reading…

2015: The Year We Finally Cured Heart Disease!

Editor’s note: Larry was too depressed to write the 2015 yearly review. Veteran healthcare journalist and eternal optimist Candide Corn volunteered to take over the task this year. Candide’s motto is “all is for the best in the best of all possible worlds.” What a great year for cardiology! The year brought us an unending…

Click here to continue reading…

Meta-Analysis Gives More Support To Aggressive Blood Pressure Treatment

A large new meta-analysis offers fresh support to the growing movement in favor of more aggressive treatment to lower high blood pressure. The findings are consistent with and extend the results of the recently reported NIH SPRINT trial, which found substantial clinical benefits for a systolic blood pressure target of 120 mm Hg instead of 140…

Click here to continue reading…

Prepublish or Perish? Making a Case for Medicine to Take a Cue from Basic Science

  It’s time for clinical research to join other scientific fields like physics and computer science and encourage preprint publication of manuscripts on the internet, according to three top cardiologists writing in a Lancet comment. Since 1969 researchers have labored under the constraints of the Ingelfinger rule, in which “posting a paper, data, or key findings on the internet represented presubmission…

Click here to continue reading…

NIH Trial, Stopped Early, Supports More Intensive Blood Pressure Targets

More stringent blood pressure targets could save lives and reduce cardiovascular events, according to preliminary results from a large NIH clinical trial that was stopped early. The SPRINT (Systolic Blood Pressure Intervention Trial) trial randomized 9,361 hypertensive patients 50 years of age or older to the standard systolic blood pressure target (when the trial began) of 140…

Click here to continue reading…

Cardiologist William Maisel Arrested In Prostitution Sting Operation

Cardiologist William Maisel, the deputy director for science at the FDA Center of Devices and Radiological Health, was arrested on prostitution charges after being caught in an undercover sting operation in North Laurel, Maryland. Maisel was one of 10 men arrested on July 13. The Savage-Guilford Patch reported that Maisel “approached a plain-clothed female police officer and…

Click here to continue reading…

Robert Hauser, ICD Watchdog, Offers Viewpoint On Riata Controversy At HRS

Editor’s Note: The following guest post is published with the permission of its author,  Edward J. Schloss, MD, (Twitter ID @EJSMD) the medical director of cardiac electrophysiology at Christ Hospital in Cincinnati, OH. Robert Hauser, ICD Watchdog, Offers Viewpoint On Riata Controversy At HRS by Edward J Schloss MD The St. Jude Riata ICD lead controversy took…

Click here to continue reading…

St. Jude Seeks Retraction of Hauser Article On Riata Leads

St. Jude Medical is seeking the retraction of an article by Robert Hauser in Heart Rhythm linking the company’s Riata and Riata ST leads to 20 or more deaths. In a press release (see below) issued on Friday afternoon, St. Jude alleges numerous mistakes and oversights in the Hauser paper. In a brief statement to CardioBrief, Hauser wrote:…

Click here to continue reading…

Software Tool Could Provide Early Warning of ICD Lead Failure

In recent years defects in ICD leads have caused recalls and provoked broad concerns among health care professionals and patients alike about the safety and reliability of ICDs and other implanted cardiac devices. Now a key player in these events proposes that a computer software program can better monitor ICD leads and provide earlier warnings…

Click here to continue reading…

ACCORD fails to find benefits for fenofibrate or lower blood pressure target

When added to statins, fenofibrate failed to improve outcome in patients with type 2 diabetes. In addition, lowering systolic blood pressure to 120 mm Hg or lower was no better than the traditional target of 140 mm Hg. These are the main results of the two arms of ACCORD (Action to Control Cardiovascular Risk in…

Click here to continue reading…

Cardio-Sis in the Lancet: is 130 the new 140?

Cardio-Sis, a large trial from Italy, provides the first good evidence that systolic blood pressure goals in non-diabetic patients should be lowered to 130 mm Hg. Most guidelines now recommend that systolic blood pressure be reduced to below 140 mm Hg, though in diabetics it is now generally accepted that the target should be 130…

Click here to continue reading…

NY Times: why is the ICD registry languishing?

 In 2004 Medicare mandated the creation of a national ICD registry, which has been run since then by the ACC and HRS. Now, New York Times reporter Barry Meier, who has been instrumental in bringing to light ICD problems in the past, notes in a February 26 story that the ICD registry is languishing for lack…

Click here to continue reading…

Judge who ruled in favor of Medtronic failed to disclose family link to company

The judge who ruled in Medtronic’s favor by dismissing a big lawsuit against the company didn’t disclose that his son is a partner in a law firm that has Medtronic as a client, according to a story by Thomas Burton in Friday’s Wall Street Journal. Applying the principle of preemption, which……

Click here to continue reading…

Court dismisses complaint against Medtronic over Fidelis leads

A US District Court has dismissed a case against Medtronic over the Fidelis lead failures. The decision follows the significant precedent-setting Supreme Court decision last year in Riegel v Medtronic. You can read the Wall Street Journal story or the Medtronic press release by clicking below….

Click here to continue reading…